tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MRKR Stock Latest News

Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
Company AnnouncementsMarker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
3d ago
MRKR
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
PremiumCompany Announcements
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
3d ago
MRKR
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
PremiumCompany Announcements
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
24d ago
MRKR
Marker Therapeutics announces first patient treated in off-the-shelf program
PremiumThe Fly
Marker Therapeutics announces first patient treated in off-the-shelf program
24d ago
MRKR
Marker Therapeutics Reports Promising Phase 1 Study Results
PremiumCompany Announcements
Marker Therapeutics Reports Promising Phase 1 Study Results
2M ago
8K
MRKR
Marker Therapeutics provides update on observations from Phase 1 APOLLO study
PremiumThe FlyMarker Therapeutics provides update on observations from Phase 1 APOLLO study
2M ago
MRKR
Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline
Premium
Company Announcements
Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline
3M ago
MRKR
Promising Developments and Market Potential Drive Buy Rating for Marker Therapeutics
Premium
Ratings
Promising Developments and Market Potential Drive Buy Rating for Marker Therapeutics
3M ago
MRKR
Strategic Collaborations and Promising Clinical Developments Drive Buy Rating for Marker Therapeutics
PremiumRatings
Strategic Collaborations and Promising Clinical Developments Drive Buy Rating for Marker Therapeutics
4M ago
MRKR
Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing
PremiumCompany Announcements
Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing
5M ago
8K
MRKR
Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601
PremiumThe Fly
Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601
5M ago
MRKR
Marker Therapeutics Concludes Annual Stockholders Meeting
PremiumCompany Announcements
Marker Therapeutics Concludes Annual Stockholders Meeting
5M ago
8K
MRKR
Marker Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsMarker Therapeutics Reports Q1 2025 Financial Results
5M ago
MRKR
Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
Premium
Ratings
Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
5M ago
MRKR
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells
Premium
Company Announcements
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells
5M ago
MRKR
Marker Therapeutics reports evidence from Phase 1 APOLLO study
PremiumThe Fly
Marker Therapeutics reports evidence from Phase 1 APOLLO study
5M ago
MRKR
Marker Therapeutics Advances T Cell Therapies in 2024
PremiumCompany Announcements
Marker Therapeutics Advances T Cell Therapies in 2024
6M ago
MRKR
Marker Therapeutics: Strong Buy Rating Backed by Innovative MAR-T Cell Therapy and Robust Financial Position
PremiumRatings
Marker Therapeutics: Strong Buy Rating Backed by Innovative MAR-T Cell Therapy and Robust Financial Position
7M ago
MRKR
Marker Therapeutics Advances MT-601 with Promising Results and Strategic Funding
PremiumCompany Announcements
Marker Therapeutics Advances MT-601 with Promising Results and Strategic Funding
7M ago
MRKR
Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year
PremiumThe FlyMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year
7M ago
MRKR
Marker Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Marker Therapeutics initiated with a Buy at Canaccord
8M ago
MRKR
Marker Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Marker Therapeutics initiated with a Buy at Canaccord
8M ago
MRKR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >